Trial reportCell transplantation2013
Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience.
Trial report in Cell transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05018858 (Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Lupus), which is not on this map. Cited by 148 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Lupus
Who cites it
148 citing papers in PubMed, 3 syntheses or guidelines pooled it, 270 citations in OpenAlex.
- Stem cell injections for osteoarthritis of the knee.The Cochrane database of systematic reviews · 2025Pooled it
- Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials.Stem cell research & therapy · 2025Pooled it
- Clinical efficacy and safety of stem cell therapy for knee osteoarthritis: A meta-analysis.Medicine · 2020Pooled it
- Allogeneic umbilical cord-derived mesenchymal stromal cells for treatment of refractory lupus nephritis: a real-world study.Stem cell research & therapy · 2026Trial
- Phase II trial of intravenous human dental pulp stem cell therapy for Huntington's disease: a randomized, double-blind, placebo-controlled study.Stem cell research & therapy · 2025Trial
- Mesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial.Stem cells translational medicine · 2021Trial
- Intra-Articular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, Placebo-Controlled Clinical Trial.Stem cells translational medicine · 2019Trial
- Serum IFN-γ Predicts the Therapeutic Effect of Mesenchymal Stem Cells Transplantation in Systemic Lupus Erythematosus Patients.Stem cells translational medicine · 2017Trial
- A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2014Trial
- Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study.Arthritis research & therapy · 2014Trial
- Review
- Mesenchymal stromal cell therapy for systemic lupus erythematosus: mechanisms, clinical translation, and future directions.Stem cell research & therapy · 2026Review
- [Regulatory effects of mesenchymal stem cells on B1 cells and Tfh cells in children with systemic lupus erythematosus].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Utilization of Stem Cells in Medicine: A Narrative Review.International journal of molecular sciences · 2025Review
- Advances in mesenchymal stem cell therapy for lupus nephritis.World journal of stem cells · 2025Review
- Molecular and therapeutic effects of mesenchymal stem cell-derived exosomes on autoimmune diseases.World journal of stem cells · 2025Review
- An overview of stem cells and cell products involved in trauma injury.Regenerative therapy · 2025Review
- MSC transplantation ameliorates depression in lupus by suppressing Th1 cell-shaped synaptic stripping.JCI insight · 2025Article
- Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review.BMC nephrology · 2025Review
- Mesenchymal stem cells for immune modulation in systemic lupus erythematosus: From bench research to clinical applications.Narra J · 2024Review
88 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
Mesenchymal stem cells (MSCs) are multipotential nonhematopoietic progenitors and are capable of differentiating into several tissues of mesenchymal origin. We have shown that bone marrow-derived MSCs from both SLE patients and lupus-prone MRL/lpr mice are defective structurally and functionally. Here we observe the long-term safety and efficacy of allogeneic MSC transplantation (MSCT) in treatment-resistant SLE patients. Eighty-seven patients with persistently active SLE who were refractory to standard treatment or had life-threatening visceral involvement were enrolled. Allogeneic bone marrow or umbilical cord-derived MSCs were harvested and infused intravenously (1 × 10(6) cells/kg of body weight). Primary outcomes were rates of survival, disease remission and relapse, as well as transplantation-related adverse events. Secondary outcomes included SLE disease activity index (SLEDAI) and serologic features. During the 4-year follow-up and with a mean follow-up period of 27 months, the overall rate of survival was 94% (82/87). Complete clinical remission rate was 28% at 1 year (23/83), 31% at 2 years (12/39), 42% at 3 years (5/12), and 50% at 4 years (3/6). Rates of relapse were 12% (10/83) at 1 year, 18% (7/39) at 2 years, 17% (2/12) at 3 years, and 17% (1/6) at 4 years. The overall rate of relapse was 23% (20/87). Disease activity declined as revealed by significant changes in the SLEDAI score, levels of serum autoantibodies, albumin, and complements. A total of five patients (6%) died after MSCT from non-treatment-related events in the 4-year follow-up, and no transplantation-related adverse event was observed. Allogeneic MSCT resulted in the induction of clinical remission and improvement in organ dysfunction in drug-resistant SLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.